Experts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Ursula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Here are 3 things you should know about the multimodal treatment of patients with SCLC.
P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.
Panelists discuss the broader treatment landscape for advanced clear cell renal cell carcinoma (RCC), outlining the current standards of care, how treatment approaches vary for aggressive versus benign or indolent tumors, and the approach to shared decision-making with patients, including counseling and educating them on different treatment options.
Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
Jenifer A. Vencill, PhD, LP, highlighted that sexual dysfunction can negatively impact patients' quality of life, and how she aims to bring more awareness to this issue.
Panelists discuss how PSMA PET imaging is expected to evolve, enhancing precision in prostate cancer treatment through improved detection and staging. Medical professionals anticipate broader use in therapy guidance, with future advancements addressing gaps in early detection and metastasis, improving treatment strategies.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Judy concludes the event and presents the awards.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr, MD.
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
This segment examines Dr. Mikhael's approach to comparing ide-cel and cilta-cel for patient selection, emphasizing how patient traits, efficacy, and safety profiles influence treatment decisions across different groups.
Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.
Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.